Orchestra BioMed Holdings, Inc. Income Statement
OBIO|3 years of annual SEC 10-K data (FY2023-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 3 fiscal years. All figures from audited SEC 10-K filings.
At a glance
Revenue
$3M
FY2025
Gross Profit
N/A
FY2025
Operating Income
-$64M
FY2025
Net Income
-$61M
FY2025
Orchestra BioMed Holdings, Inc. reported $3M in revenue and $61M in net loss for FY2025. Revenue has declined at a 13.6% compound annual rate over the past 2 years.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score NaN (distress zone, below 1.23 threshold)
- Piotroski F-Score: 2/9 criteria passed
- Currently unprofitable: Net income is negative
- Cash-backed earnings: Operating cash flow exceeds net income
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Revenue | $2.6M | $2.8M | $3.5M |
| Cost of Revenue | $204.0K | $186.0K | $211.0K |
| SG&A Expense | $23.9M | $20.3M | $14.0M |
| R&D Expense | $42.8M | $33.8M | $21.9M |
| Operating Income | -$64.3M | -$51.5M | -$32.7M |
| Interest Expense | - | $1.4M | $1.3M |
| Income Tax | $0 | - | - |
| Net Income | -$61.0M | -$49.1M | -$33.6M |
| EPS (Basic) | -$1.66 | -$1.48 | -$2.24 |
| EPS (Diluted) | -$1.66 | -$1.48 | -$2.24 |
| Shares Outstanding | 38.2M | 35.8M | 20.2M |
| Operating Margin | -2437.5% | -1866.2% | -924.3% |
| Profit Margin | -2313.3% | -1779.7% | -951.3% |